Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Debra Lamont

Nurse Practitioner, Psychiatric/Mental Health Denton, TX Nurse Practitioner

NPI 1043360993 CMS profile 10610439

914 North Locust Street, North Texas Psychiatry And Psychotherapy, Denton, TX 76201

Open in the dashboard

General payments

$28,477

132 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Debra Lamont of Denton, TX is reported in the CMS Open Payments database as having received $28,477 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $126 2
2023 General $12,158 42
2022 General $6,355 38
2021 General $9,838 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Debra Lamont
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Debra Lamont were reported at $126. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Debra Lamont Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $9,838 $166 $54–$482 $132
2022 $6,355 $195 $66–$559 $149
2023 $12,158 $233 $82–$673 $160
2024 $0 $236 $84–$688 $164
2025 $126 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $26,164 71 payments
  2. Validus Pharmaceuticals LLC $966 4 payments
  3. Alkermes, Inc. $273 5 payments
  4. Otsuka America Pharmaceutical, Inc. $201 7 payments
  5. Neurocrine Biosciences, Inc. $195 8 payments
  6. ITI, Inc. $136 6 payments
  7. Sunovion Pharmaceuticals Inc. $103 6 payments
  8. Axsome Therapeutics, Inc. $61 3 payments
  9. Vanda Pharmaceuticals Inc. $55 3 payments
  10. Teva Pharmaceuticals USA, Inc. $48 2 payments
  11. Other $275 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,238 19 payments
  2. Food and Beverage $3,280 96 payments
  3. Travel and Lodging $1,912 16 payments
  4. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $26,164 71 payments
  2. Equetro $966 4 payments
  3. LYBALVI Cns $273 5 payments
  4. LYBALVI Cns $254 4 payments
  5. LYBALVI Cns $233 3 payments
  6. LYBALVI Cns $233 3 payments
  7. INGREZZA $195 8 payments
  8. REXULTI $147 4 payments
  9. CAPLYTA $136 6 payments
  10. LATUDA $103 6 payments
  11. Other $876 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

828

Median for Nurse Practitioner: 389

Drug cost

$195,556

Median for Nurse Practitioner: $21,885

Branded share of claims

30.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 17 $129,113
Rexulti Brexpiprazole Brand 18 $31,983
Trintellix Vortioxetine Hydrobromide Brand 19 $18,991
Clonazepam Generic 84 $2,054
Bupropion Xl Bupropion Hcl Brand 86 $2,046
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 37 $1,373
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 27 $1,160
Zolpidem Tartrate Er Zolpidem Tartrate Brand 22 $1,020
Carbamazepine Generic 12 $948
Lamotrigine Generic 48 $846

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record